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Muscle Nerve 58: [286] [287] [288] [289] [290] [291] [292] 2018 GNE myopathy is an autosomal recessive disorder characterized by adult-onset, slowly progressive, distal and proximal myopathy that typically leaves patients wheelchair dependent 10-20 years after onset. Histologically, it is associated with muscle fiber degeneration and formation of tubulofilamentous vacuoles in muscle tissue. [1] [2] [3] [4] [5] GNE myopathy is caused by biallelic, mostly missense mutations in the GNE gene, encoding the rate-limiting enzyme of sialic acid biosynthesis, UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE). [6] [7] [8] [9] Sialic acids are the most abundant terminal sugar residues on glycans (glycoproteins and glycolipids), where they regulate several biologic functions, including cellular interactions, adhesions, and signaling. 10, 11 The exact pathophysiology of GNE myopathy remains unknown, but the partial dysfunction in GNE enzyme activities due to missense mutations suggests involvement of impaired sialylation of muscle glycans. 12, 13 Such impaired sialylation was identified in a select group of (sialo-) glycans in GNE myopathy patients [14] [15] [16] [17] [18] ; some of the glycans may aid in diagnosing GNE myopathy. 17, 18 There are no robust biomarkers developed for diagnosis or for demonstrating intracellular response to therapy.
Lectins are sugar-binding proteins with ligand specificities for defined carbohydrate sequences. 19 Staining of GNE myopathy human and mouse muscle sections with sialic acid binding lectins or lectins binding to desialylated sugar moieties demonstrated hyposialylation of sarcolemmal membranes. 4, 12, 15, [18] [19] [20] [21] In particular, use of the lectin SNA (Sambucus nigra agglutinin) that predominantly recognizes terminal sialic acid (Neu5Ac) in an a(2,6)-linkage with either galactose or with N-acetylgalactosamine (GalNAc), [24] [25] [26] was previously proven informative for GNE myopathy muscle sialylation status. 4, 15, 18 Lectin histochemistry demonstrated that sialic acid residues in a a(2,6)-linkage with either galactose or with GalNAc, present on sarcolemmal glycans appeared to be absent or decreased in human and mouse GNE myopathy muscle sections (Supplementary Fig. S1 , which is available online). 4, 15, 18 In addition, GNE myopathy mice receiving 12 weeks of oral therapy with the sialic acid precursor Additional supporting information may be found online in the Supporting Information section at the end of the article.
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N-acetylmannosamine (ManNAc) showed resialylation of sarcolemmal membranes by lectin histochemistry ( Supplementary Fig. S1C ), 21 and ManNAc therapy ameliorated the myopathic phenotype in GNE myopathy mice. 22 These encouraging murine results suggest that lectin staining of muscle biopsies not only serves as a biomarker aiding diagnosis of GNE myopathy, 4, 18 but may also to demonstrate intracellular response to sialylationincreasing therapies. Clinical studies of oral ManNAc therapy in GNE myopathy subjects are currently ongoing (clinicaltrials.gov Identifier NCT02346461) 4, 23 and a robust biomarker of intracellular response to therapy of skeletal muscle, the only affected tissue in GNE myopathy, is pivotal for demonstration of biochemical efficacy.
Therefore, we sought to develop SNA lectin staining of skeletal muscle biopsies as a biomarker for GNE myopathy. GNE myopathy patients' muscle biopsies are available, because they are often acquired as part of the diagnostic evaluation. 1, 2, 4, 5 In previous lectin studies for human GNE myopathy muscle biopsy sections, either paraffin embedded 4, 18 or frozen, 12, 15 were imaged and presented in a qualitative way, with the investigator determining the microscope settings and the muscle region in the biopsy appropriate for imaging. Here, we present a standardized, reproducible method to image and quantify fluorescent lectin binding to muscle membranes (marked by sarcolemma residence protein caveolin-3 [CAV-3]) in entire muscle biopsy slides.
MATERIALS AND METHODS
Subjects and Muscle Biopsies. Frozen human control muscle biopsy slides (n 5 4) and human GNE myopathy muscle biopsy slides (n 5 6) ( Table 1) was obtained from all muscle biopsy donors. Biopsies were frozen in 2-methylbutane, cooled in liquid nitrogen, and cut into 8-mm cross-sections.
Sectioning and Fluorescence Staining. Muscle sections were double stained with CAV-3 antibody (R&D Systems, Minneapolis, MN) and SNA lectin (Vector Laboratories). The CAV-3 protein is not glycosylated and is found in plasma membranes of most cell types. CAV-3 antibodies are commonly used as sarcolemma markers in muscle imaging studies. 27, 28 The lectin SNA predominantly recognizes Neu5Ac in an a(2,6)-linkage with either galactose or with GalNAc. [24] [25] [26] Slides containing frozen muscle sections were transferred from -80 8C storage into prechilled glass dishes and thawed to room temperature for 30 min. Staining for all 9 slides (GNE myopathy and controls) was performed in 1 batch under the same conditions. Thawed muscle sections were fixed in acetone for 20 min, followed by 1 min of air drying and washing with phosphate-buffered saline (PBS) for 10 min. The fixed muscle sections were then blocked at room temperature with 1 3 Carbo-Free Blocking solution (Vector Laboratories, Burlingame, CA) for 1 h, followed by overnight incubation at 4 8C in a mixture of 8 mg/ml CAV-3 antibody (R&D Systems, Minneapolis, MN) and 5 mg/ml fluorescein isothiocyanate (FITC)-labeled SNA lectin (Vector Laboratories) in Carbo-Free Blocking solution. Next, the sections were washed at room temperature 3 times 5 min with 0.1% Tween/PBS and 5 min with PBS. The slides were then incubated at room temperature for 1 h with secondary antibodies (to visualize CAV-3 antibody staining) donkey anti-mouse AlexaFluor555 (A-31570, Invitrogen/ Thermo Fisher Scientific, Rockville, MD) in Carbo-Free Blocking solution. After washing again 3 times 5 min with 0.1% Tween/PBS and 5 min with 1 3 PBS, the slides were mounted with Vectashield containing the nuclear dye 4 0 ,6-diamidine-2 0 -phenylindole dihydrochloride (DAPI, Vector Laboratories).
Image Acquisition Procedure by Inverted Microscopy.
Imaging was performed on an Axio Observer Z1 inverted microscope (Zeiss Microimaging Inc, Thornwood, NY) with a 20 3 DIC objective, using an Axiocam MRm Rev 3 digital camera with Colibri LED illumination (Zeiss Microimaging Inc). Image settings were established on a control stained muscle slide. Entire muscle sections on each slide were digitally imaged using Tile-imaging (with local focus surface support points, 10% Tile Overlap) and Z-stack imaging (5 Z-slices per slide; 8 mm range, 2-mm interval slices) using ZEN2 Pro software (Zeiss Microimaging Inc.). All slides were imaged in one session with the same microscope settings. Image processing was performed with ZEN2 Pro software, the focus planes of the entire Z-Stack image was calculated to one extended depth of focus image with Maximum Projection parameters. All tiles were stitched together into 1 image file by stitching processing.
Selected Area Imaging by Confocal Microscopy. After finalizing the Tile-imaging for each slide, 4-5 selected areas in each slide were also digitally imaged as a Z-stack with a Zeiss LSM 510 META confocal laser-scanning microscope (Zeiss Microimaging Inc). Images were acquired using a Plan-Apochromat 20 3 DIC objective. All confocal images are displayed as 1D projections of confocal Z-stacks (Supplementary Fig. S1 ).
Membrane Fluorescence Quantitation with Image
Analysis Software. Image analysis of SNA/CAV-3 fluorescent image files was performed using Definiens Architect Software (Definiens, Cambridge, MA) with specialized algorithms and applications. Entire image files (Fig. 1A and B) were imported in the software. Nonspecific artifacts/fluorescence, scrambled biopsy edges and nonmuscle or nonintact areas (i.e., mostly fibrous tissue areas) (Fig. 1C) were manually annotated in each image file to be excluded from analysis (Fig. 1D ). Images were analyzed automatically in one batch. For image analysis, the CAV-3 fluorescent area was identified by the software and set as a mesh for sarcolemma membrane area (Fig. 1E) . The software then determined the SNA fluorescent signal co-localization (intensity [pixels], area of fluorescence) on the CAV-3 mesh (Fig. 1F) . The software provided fluorescence quantitation per image file in the following outputs: (1) area of SNA fluorescence colocalized on CAV-3 mesh (area is calculated in pixels); (2) total intensity of SNA fluorescence co-localized on CAV-3 mesh (intensity is calculated by sum of intensity and nuber of pixels).
In addition, the number of cells per biopsy was manually determined, using ImageJ software (NIH, Bethesda, MD). The diameter per cell was manually annotated with Image J software (annotated as narrowest distance at/near center of each cell), which was used to determine membrane length per cell and average membrane length per cell for each biopsy (calculated with Image J software).
Statistical Analysis. Statistical analysis of fluorescence quantitation was analyzed with the Mann-Whitney unpaired t-test.
RESULTS
The biopsy donors in both the control and GNE myopathy groups were comparable in male/ female distribution, range of age at biopsy, and variation in GNE gene mutations, and most biopsies were acquired from the biceps branchii (Table  1) . Each biopsy was of adequate quality with a large number of intact muscle cells per biopsy slide (range 1,223-13,304 total cells) ( Table 1 , Supplementary Fig. S2 ). The average cell membrane length varied from 11.53 to 23.81, reflecting the cut of each biopsy (pure cross-section or more longitudinal cut resulting in larger cells).
Each biopsy slide was double-stained with FITClabeled SNA lectin and CAV-3 antibodies (visualized with AlexaFluor555-labeled secondary antibodies). Initial qualitative imaging on muscle biopsy sections showed that, in frozen sections, the SNA fluorescent signal is less distinctive than in paraffin embedded sections (Supplementary Figs. S1A and S1C), which called for quantitation of the SNA fluorescent signal.
To standardize quantitative lectin analysis, staining methods and imaging procedures were optimized using control and GNE myopathy muscle slides. All biopsies were stained with SNA and CAV-3 in one batch, followed by imaging entire tissue sections on each slide in one batch by Tile and Z-stack imaging in automated manner with similar microscope settings by the same investigator. One image file was created for each biopsy, with annotations for regions to exclude from analysis ( Fig. 1,  Supplementary Fig. S2 ), followed by quantitative analysis of fluorescent area and intensity in each image file (Table 1) .
Because the size and quality of each biopsy varied, we used the relative measures SNA area and SNA intensity colocalized with CAV-3 per biopsy as outcome parameters, and divided them by the average length of cells per biopsy to correct for a different cut (cross-section cut versus more longitudinal cut) of each biopsy. These values were averaged for each group (control and GNE myopathy) of biopsies. Both the SNA area (299.5 3 10 3 in control group vs. 137.6 3 10 3 in GNE Myopathy group) and SNA intensity (97.5 3 10 6 in control group vs. 48.1 3 10 6 in GNE Myopathy group) colocalized with CAV-3 per the average cell length showed a 50% decrease in the GNE myopathy group compared with the control group (Table 1) . Although substantial, this difference was not statistically significant (unpaired t-test; P 5 0.0667; Fig. 2 ). 
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Here we assessed quantitative analysis of SNA fluorescent signal in entire muscle biopsy slides as a biomarker for GNE myopathy, which is associated with impaired sarcolemma sialylation. The quantitative analysis method described in this manuscript includes standardized fluorescent staining and imaging of entire cross-section biopsy slides, with unbiased software analysis of the image files. This software program has previously been used in muscle image analysis for other purposes. 31 Previous imaging demonstrated that SNAreactive glycans are expressed at muscle membranes and all muscle fibers appear to express SNA-reactive glycans equally, 4, 15, 18, 21 Therefore, we imaged entire muscle sections and included each intact muscle cell (stained by caveolin) in our analysis.
Even with the small number of biopsies per group, we demonstrated that average areas and intensities of SNA fluorescence per CAV-3 area was 50% (P 5 0.0667) reduced in GNE myopathy biopsies compared with controls. Statistical significance was absent likely to the limited number of biopsies in each group. These findings are in line with previously published, sometimes subtle, qualitative GNE myopathy lectin imaging results. 12, 15, 18 The use of the nonglycosylated protein, CAV-3, as sarcolemma marker proved appropriate, because CAV-3 is evenly distributed among FIGURE 2. Dot plots of fluorescence quantitation results. Dot plots of SNA/Cav-3 area (A) and SNA/CAV-3 intensity (B) results, comparing control muscle biopsies (n 5 4) with GNE myopathy muscle biopsies (n 5 6). A difference in fluorescence expression between groups is present with each output parameter, although not statistically significant (Mann-Whitney unpaired t-test P value 0.0667 for both parameters).
sarcolemma membranes and muscle fiber types. The use of a software program for muscle membrane analysis using CAV-3 as a mesh, as established in this manuscript, is easily adaptable for any other purpose involving expression analysis of muscle membrane components, and may be of benefit for disorders in which therapeutic changes in expression are subtle and difficult to assess by other methods.
For future use of this method for diagnosing GNE myopathy, ranges of normal and disease fluorescence intensities/areas need to be established in a larger group of control and GNE myopathy muscle biopsies. A suspected GNE myopathy diagnosis based on muscle biopsy lectin analysis needs to be confirmed by genetic analysis identifying biallelic mutations in the GNE gene, because it is possible that other muscle disorders (e.g., dystroglycanopathies) show decreased sialylation/glycosylation of sarcolemma membranes. 32 Our established quantitation method is wellsuited to demonstrate response to therapy, particularly in muscle biopsies of the same muscles in the same individuals acquired before and after therapy. We have now established and validated this method for GNE myopathy muscle biopsies, and intend to apply it to muscle biopsies acquired in our ongoing Phase 2 clinical trial of ManNAc for GNE myopathy (clinicaltrials.gov Identifier NCT02346461).
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